Home >> Publications >> Author >> Griesinger, Christian
5. Februar 2018
Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N
31. Mai 2019
Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model
Wegrzynowicz, M.Bar-On D, Calo L, Anichtchik O, Iovino M, Xia J, Ryazanov S, Leonov A, Giese A, Dalley JW, Griesinger C, Ashery U, Spillantini MG
1. August 2019
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, Peters F, von Ungern-Sternberg B, Ryazanov S, Leonov A, Griesinger C, Zwergal A, Levin J, Bartenstein P, Yakushev I, Cumming, P, Boening G, Ziegler S, Herms J, Giese A, Rominger A
13. Dezember 2019
The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers
Saravanan MS, Ryazanov S, Leonov A, Nicolai J, Praest P, Giese A, Winter R, Khemtemourian L, Griesinger C, Killian JA
20. Dezember 2019
(11) C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to alpha-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier
Maurer A, Leonov A, Ryazanov S, Herfert K, Kuebler L, Buss S, Schmidt F, Weckbecker D, Linder R, Bender D, Giese A, Pichler BJ, Griesinger C
30. Juli 2020
Effects of pharmacological modulators of α‐synuclein and tau aggregation and internalization
Dominguez-Meijide A, Vasili E, König A, Cima-Omori MS, Ibáñez de Opakua A, Leonov A, Ryazanov S, Zweckstetter M, Griesinger C, Outeiro TF
30. Juli 2020
Dopamine promotes the neurodegenerative potential of β-synuclein
Raina A, Leite K, Guerin S, Mahajani SU, Chakrabarti KS, Voll D, Becker S, Griesinger C, Bähr M, Kügler S

Open Positions